Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Deltex Medical cherry-picks two new directors

Deltex Medical cherry-picks two new directors

Deltex Medical (LON:DEMG) plans to appoint two new non-executive directors to replace a pair of retiring board members.

Tim Irish and Mark Wippell have been cherry-picked as the men to take over from vice-chairman Dr Ed Snape and Professor Sir Duncan Nichol.

Irish, 49, has close to 30 years’ experience in the healthcare industry, having been head of marketing and strategy for Phillips Medical and a vice president for GE Medical in Europe.

Deltex said he has substantial experience in marketing medical products in a number of its key existing markets.

Wippell, 55, is a partner with Allen & Overy. His track record includes public and private M&A, business reorganisations, joint ventures and demergers.

Snape will retire after the AGM on 7 May and Nichol will depart after the interim results are published in September.

Chairman Nigel Keen welcomed Irish and Wippell to the board, highlighting their experience that he hopes will “aid the further development of Deltex and its growing market focus, particularly in the USA”.

“The board would like to thank Ed and Duncan for their significant contribution over the years. We wish them both well in their retirement from Deltex Medical,” Keen added.

Timeline

Related Articles

June 25
Venn doubled sales last year, and looks set to do the same thing this time around. But is it getting any credit for this stellar performance?
July 14
OptiBiotix is described as a “sweet opportunity” by the research house Hybridan, which recently started coverage of the AIM-listed company
May 13
Constellation Healthcare Technologies is raising £12.9mln that will be used to tap into a ‘pipeline’ of acquisition opportunities.

© Proactive Investors 2015